Modern Alpha Content Hub Biden’s “Cancer Moonshot” Brings Biotech Focus Back to U.S. By Karrie GordonSeptember 15, 2022
Disruptive Technology Content Hub Change the DNA of Your Portfolio: Growth Opportunities Through Genomics By Max ChenJune 7, 2022
Thematic Investing Content Hub Innovation Should Help Fuel Growth in This China Biotech ETF By Ben HernandezApril 11, 2022
Beyond Basic Beta Content Hub Vaccine Stocks Lift Biotech ETFs as China Enters Lockdowns By Max ChenMarch 14, 2022
Innovative ETFs Content Hub An ETF to Capture Promising Biotech Innovators By Max ChenJanuary 12, 2022
Nasdaq Investment Intelligence Content Hub How to Invest in Biotech in 2022 By Karrie GordonDecember 15, 2021
Leveraged & Inverse Content Hub Direxion Launches mRNA Technology-Focused ETF By Karrie GordonDecember 9, 2021
Innovative ETFs Content Hub Moderna’s Omicron Booster Strategy Lifts Biotechnology ETFs By Max ChenNovember 29, 2021
Innovative ETFs Content Hub Pfizer’s COVID-19 Pill Has Mixed Results for Healthcare ETFs By Max ChenNovember 5, 2021
Innovative ETFs Content Hub Moderna Vaccine Is Granted Authorization in Australia By Max ChenAugust 9, 2021
Innovative ETFs Content Hub A Biotech ETF to Track Nasdaq’s Industry-Setting Benchmark By Max ChenJune 30, 2021
Innovative ETFs Content Hub The Biotech Trek: A Short History from 1993 to 2021 By Max ChenJune 29, 2021
Modern Alpha Content Hub The BioRevolution: An ETF That Taps Into Nearly Everything By Max ChenJune 21, 2021
